AstraZeneca Loses Bid To Revive Patent For Diabetes Drug
The Court of Appeal refused Wednesday to revive AstraZeneca's intellectual property protections for its billion-dollar diabetes drug, opening the way for generic competition to hit the market....To view the full article, register now.
Already a subscriber? Click here to view full article